Biologics for Rheumatoid Arthritis: Onset Timelines by Agent

Time to Clinical Response (ACR20/50)

Biologic (target)	Typical onset	Key notes
Adalimumab (TNF-α)	2–4 weeks	SC q2w; citrate-free formulation less painful
Etanercept (TNF-α)	1–2 months	SC weekly; lower TB reactivation risk
Infliximab (TNF-α)	2–4 weeks	IV q8w; infusion reactions; combo with MTX reduces antibodies
Certolizumab (TNF-α)	2–4 weeks	PEGylated Fab'; no Fc — safe in pregnancy
Golimumab (TNF-α)	2–4 weeks	SC q4w; once-monthly convenience
Abatacept (CTLA-4-Ig)	2–4 months	IV/SC; distinct mechanism; good safety in elderly
Rituximab (CD20)	4–8 weeks (post-2nd infusion)	Two 1g IV infusions 2 wks apart; B-cell depletion
Tocilizumab (IL-6R)	2–4 weeks	IV/SC; monitor neutrophils, platelets, lipids
Sarilumab (IL-6R)	2–4 weeks	SC q2w; higher dose option
Ixekizumab (IL-17A)	2–4 weeks	Also approved for PsA, axial SpA
Brodalumab (IL-17RA)	2–4 weeks	Suicidality warning; REMS program

Real-World Variables

• Prior biologic failure → slower/less response.
• Concomitant csDMARD (esp. MTX) improves drug survival.
• High baseline CRP/ESR predicts better TNFi response.
• Obesity reduces TNFi efficacy (dose by weight for infliximab).

Monitoring & Expectations

1. Assess at 12–16 weeks (ACR20/50, DAS28, CDAI).
2. If inadequate → switch mechanism (not another TNFi).
3. Infection vigilance: screen TB, hepatitis; vaccinate pre-start.

Biologics transform RA outcomes; matching agent to patient phenotype optimizes speed and durability of response.